TNF Pharmaceuticals (NASDAQ:TNFA) Stock Price Down 12.7% – Here’s What Happened

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA)’s share price dropped 12.7% during trading on Friday . The company traded as low as $2.9807 and last traded at $3.08. Approximately 360,673 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 3,511,287 shares. The stock had previously closed at $3.53.

Analysts Set New Price Targets

Several equities research analysts have recently commented on TNFA shares. Weiss Ratings restated a “sell (e)” rating on shares of TNF Pharmaceuticals in a report on Saturday, September 27th. Wall Street Zen raised shares of TNF Pharmaceuticals to a “sell” rating in a research report on Friday, September 5th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

TNF Pharmaceuticals Price Performance

The firm has a market cap of $5.69 million, a P/E ratio of -0.01 and a beta of 2.04. The company has a fifty day moving average of $4.01 and a 200-day moving average of $10.10.

TNF Pharmaceuticals (NASDAQ:TNFA) last posted its quarterly earnings data on Tuesday, August 19th. The company reported ($18.00) earnings per share (EPS) for the quarter.

TNF Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.